RS50229B - Analozi vitamina d3 - Google Patents

Analozi vitamina d3

Info

Publication number
RS50229B
RS50229B YU92701A YUP92701A RS50229B RS 50229 B RS50229 B RS 50229B YU 92701 A YU92701 A YU 92701A YU P92701 A YUP92701 A YU P92701A RS 50229 B RS50229 B RS 50229B
Authority
RS
Serbia
Prior art keywords
alkyl
denotes
analogs
vitamin
fluoro
Prior art date
Application number
YU92701A
Other languages
English (en)
Inventor
Andrew David Batcho
Bernard Michael Hennessy
Milan Radoje Uskokovic
Original Assignee
F. Hoffmann-La Roche Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag., filed Critical F. Hoffmann-La Roche Ag.,
Publication of YU92701A publication Critical patent/YU92701A/sh
Publication of RS50229B publication Critical patent/RS50229B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Jedinjenje opšte formule u kojoj R1 označava vodonik ili C1-C4-alkil-grupu, R2 označava vodonik ili C1-C4-alkil-grupu ili R1, R2 i C20 zajedno označavaju ciklopropil, A označava R3 označava C1-C4-alkil, hidroksi-C1-C4-alkil ili fluor-C1-C4-alkil i R4 označava C1-C4-alkil, hidroksi-C1-C4-alkil ili fluor-C1-C4-alkil. Prijava sadrži još 6 patentnih zahteva.
YU92701A 1999-07-12 2000-07-06 Analozi vitamina d3 RS50229B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14341399P 1999-07-12 1999-07-12

Publications (2)

Publication Number Publication Date
YU92701A YU92701A (sh) 2004-09-03
RS50229B true RS50229B (sr) 2009-07-15

Family

ID=22503954

Family Applications (1)

Application Number Title Priority Date Filing Date
YU92701A RS50229B (sr) 1999-07-12 2000-07-06 Analozi vitamina d3

Country Status (36)

Country Link
US (1) US6331642B1 (sr)
EP (1) EP1200399B1 (sr)
JP (1) JP3803579B2 (sr)
KR (1) KR100477161B1 (sr)
CN (1) CN1174964C (sr)
AR (1) AR024695A1 (sr)
AT (1) ATE262508T1 (sr)
AU (1) AU779408B2 (sr)
BR (1) BR0012419A (sr)
CA (1) CA2378803C (sr)
CO (1) CO5190683A1 (sr)
DE (1) DE60009303T2 (sr)
DK (1) DK1200399T3 (sr)
EG (1) EG23909A (sr)
ES (1) ES2215707T3 (sr)
GC (1) GC0000198A (sr)
HK (1) HK1047578B (sr)
HR (1) HRP20020007A2 (sr)
HU (1) HUP0202157A3 (sr)
IL (2) IL147254A0 (sr)
JO (1) JO2255B1 (sr)
MA (1) MA26808A1 (sr)
MX (1) MXPA02000313A (sr)
MY (1) MY122633A (sr)
NO (1) NO20020161L (sr)
NZ (1) NZ516339A (sr)
PE (1) PE20010328A1 (sr)
PL (1) PL201877B1 (sr)
PT (1) PT1200399E (sr)
RS (1) RS50229B (sr)
RU (1) RU2235721C2 (sr)
TR (1) TR200200054T2 (sr)
TW (1) TWI268276B (sr)
UY (1) UY26239A1 (sr)
WO (1) WO2001004089A1 (sr)
ZA (1) ZA200110487B (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314427A4 (en) * 2000-08-17 2006-05-03 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT FOR THE TREATMENT OF OSTEOPOROSIS
DE60142313D1 (de) 2000-10-02 2010-07-15 Univ Emory Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
RU2296121C2 (ru) * 2001-09-21 2007-03-27 Ф.Хоффманн-Ля Рош Аг Соединения, способ их получения, способы лечения
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CA2524026A1 (en) * 2003-04-30 2004-11-18 Bioxell S.P.A. Gemini vitamin d3 compounds and methods of use thereof
US20050113348A1 (en) * 2003-06-12 2005-05-26 Yanchun Li Vitamin D and vitamin D analogs or derivatives as new anti-hypertensive agents
GB2407499B (en) * 2003-11-03 2008-02-27 Bioxell Spa Vitamin D3 analogue for use in the treatment of BPH
BRPI0414701A (pt) * 2003-09-24 2006-11-14 Bioxell Spa uso de um composto de vitamina d, método de prevenção ou tratamnento de disfunção de bexiga em um paciente, composto de vitamina d, e, kit
AU2004203436A1 (en) * 2003-09-24 2005-04-14 Bioxell Spa Compound and use in treatment
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
CN101106985A (zh) * 2004-09-24 2008-01-16 拜奥艾克塞尔股份公司 20－环烷基，26,27－烷基/卤代烷基维生素d3化合物及其使用方法
CA2586679A1 (en) 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
JP5480131B2 (ja) * 2007-05-30 2014-04-23 シトクロマ インコーポレイテッド ホスフィンオキシドビタミンｄ前駆物質の製造方法
CN107469077A (zh) 2008-04-11 2017-12-15 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
EP2682386B1 (en) * 2011-03-02 2016-08-17 Nihon University Novel vitamin d receptor modulator with partial agonist activity
KR102523660B1 (ko) 2016-09-26 2023-04-19 (주)하이플 박스용 테두리 부재보강부재와 에셈블리컨테이너 원터치크립이 포함된 박스

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749710A (en) 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
US5087619A (en) * 1988-01-20 1992-02-11 Hoffman-La Roche Inc. Vitamin D3 analogs
ZA8923B (en) * 1988-01-20 1989-09-27 Hoffmann La Roche 16-dehydro-vitamin d3-derivatives
CA2096105A1 (en) * 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
US5401733A (en) * 1993-10-01 1995-03-28 Hoffmann-La Roche Inc. Stable and active metabolites of 1,25-dihydroxy-16-ene-cholecalciferol
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
US6040300A (en) * 1995-04-07 2000-03-21 Arch Development Corporation Method of preventing colon cancer with vitamin D3 analogues
AU708679B2 (en) 1996-03-21 1999-08-12 F. Hoffmann-La Roche Ag 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives

Also Published As

Publication number Publication date
CA2378803A1 (en) 2001-01-18
ATE262508T1 (de) 2004-04-15
HK1047578B (zh) 2005-04-29
US6331642B1 (en) 2001-12-18
AR024695A1 (es) 2002-10-23
TR200200054T2 (tr) 2002-06-21
DE60009303D1 (de) 2004-04-29
DE60009303T2 (de) 2005-02-24
AU6689400A (en) 2001-01-30
HRP20020007A2 (en) 2003-04-30
DK1200399T3 (da) 2004-07-19
RU2235721C2 (ru) 2004-09-10
NO20020161D0 (no) 2002-01-11
YU92701A (sh) 2004-09-03
EP1200399A1 (en) 2002-05-02
MA26808A1 (fr) 2004-12-20
KR20020033728A (ko) 2002-05-07
IL147254A (en) 2006-07-05
JO2255B1 (en) 2004-10-07
BR0012419A (pt) 2002-03-26
HUP0202157A2 (en) 2002-10-28
MXPA02000313A (es) 2002-06-21
TWI268276B (en) 2006-12-11
PE20010328A1 (es) 2001-03-22
PL356124A1 (en) 2004-06-14
WO2001004089A1 (en) 2001-01-18
EG23909A (en) 2007-12-30
AU779408B2 (en) 2005-01-20
CN1360572A (zh) 2002-07-24
NZ516339A (en) 2003-07-25
JP3803579B2 (ja) 2006-08-02
HUP0202157A3 (en) 2004-04-28
KR100477161B1 (ko) 2005-03-18
MY122633A (en) 2006-04-29
IL147254A0 (en) 2002-08-14
HK1047578A1 (en) 2003-02-28
GC0000198A (en) 2006-03-29
ES2215707T3 (es) 2004-10-16
ZA200110487B (en) 2003-03-20
PT1200399E (pt) 2004-06-30
CN1174964C (zh) 2004-11-10
UY26239A1 (es) 2000-10-31
EP1200399B1 (en) 2004-03-24
JP2003504354A (ja) 2003-02-04
PL201877B1 (pl) 2009-05-29
NO20020161L (no) 2002-01-11
CO5190683A1 (es) 2002-08-29
CA2378803C (en) 2009-01-27

Similar Documents

Publication Publication Date Title
RS50229B (sr) Analozi vitamina d3
AP2002002637A0 (en) Novel piperazine
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
DE60012188D1 (de) Fungizide
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
RS49673B (sr) Inhibitori sintaze azot-monoksida
CY1109989T1 (el) 3,4-di-υποκαθισταμενες cyclobutene-1,2-diones ως συνδετες του υποδοχεα των cxc-χημειοκινων
BG106585A (en) Kinase inhibitors as therapeutic agents
RS53428B (sr) Kompozicije i antivirusna aktivnost supstituisanih azaindoloksosirćetnih piperazin derivata
ATE403429T1 (de) Spiropyrazol-verbindungen
SE0004245D0 (sv) Novel compounds and their use
AU2001266575A1 (en) Chemical compounds
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
WO2002000638A3 (en) Substituted phthalides as anti-convulsive drugs
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
RS50002B (sr) Eletriptan hidrobromid monohidrat
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DK1204659T3 (da) Serotonerge benzofuraner
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
DE60216948D1 (en) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
DE60005517D1 (de) Kaliumkanal-blockierende mittel